Previous 10 | Next 10 |
CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today ann...
Mersana Therapeutics, Inc. (MRSN) Q4 2020 Earnings Conference Call February 26, 2021, 08:00 AM ET Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President and Chief Executive Officer Arvin Yang - Senior Vice President...
Mersana Therapeutics (MRSN): Q4 GAAP EPS of -$0.42 misses by $0.10.Revenue of $0.01M (-75.0% Y/Y) misses by $0.06M.Press Release For further details see: Mersana Therapeutics EPS misses by $0.10, misses on revenue
- UPLIFT, a single-arm registration strategy evaluating upifitamab rilsodotin (UpRi) in platinum-resistant ovarian cancer, on track to begin in Q1 2021 - Significantly progressed pipeline of ADC candidates from the Company’s innovative Dolasynthen and Immunosynthen platform...
After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months. Another bounce back may emerge again with an insider purchasing shares after a one-day plunge of nearly 3...
CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
Mersana Therapeutics (MRSN) gaining 5.7% after activist Sarissa Capital disclosed a 5.5% stake in a 13G filing, up from an earlier stake of 4.1%.The increased stake is interesting in that Mersana CEO is familiar to Sarissa as the fund targeted Ariad Pharma and Bioverativ, wher...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...